These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 22354739

  • 1. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.
    Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, Tang D, Zhang-Auberson L, Kira J.
    Mult Scler; 2012 Sep; 18(9):1269-77. PubMed ID: 22354739
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [Abstract] [Full Text] [Related]

  • 3. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.
    Kira J, Itoyama Y, Kikuchi S, Hao Q, Kurosawa T, Nagato K, Tsumiyama I, von Rosenstiel P, Zhang-Auberson L, Saida T.
    BMC Neurol; 2014 Jan 29; 14():21. PubMed ID: 24475777
    [Abstract] [Full Text] [Related]

  • 4. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
    Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L, FTY720D2201 Study Group.
    Mult Scler; 2010 Feb 04; 16(2):197-207. PubMed ID: 20028707
    [Abstract] [Full Text] [Related]

  • 6. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW, FTY720 D2201 Study Group.
    N Engl J Med; 2006 Sep 14; 355(11):1124-40. PubMed ID: 16971719
    [Abstract] [Full Text] [Related]

  • 7. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):402-15. PubMed ID: 20089954
    [Abstract] [Full Text] [Related]

  • 8. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L, FREEDOMS study group.
    Lancet Neurol; 2012 May 04; 11(5):420-8. PubMed ID: 22494956
    [Abstract] [Full Text] [Related]

  • 9. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
    Kappos L, O'Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, Ritter S, Schlosshauer R, von Rosenstiel P, Zhang-Auberson L, Francis G.
    Neurology; 2015 Apr 14; 84(15):1582-91. PubMed ID: 25795646
    [Abstract] [Full Text] [Related]

  • 10. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B, Ross AP, Tobias K.
    Int J Clin Pract; 2011 Aug 14; 65(8):887-95. PubMed ID: 21679286
    [Abstract] [Full Text] [Related]

  • 11. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
    Gold R, Comi G, Palace J, Siever A, Gottschalk R, Bijarnia M, von Rosenstiel P, Tomic D, Kappos L, FIRST Study Investigators.
    J Neurol; 2014 Feb 14; 261(2):267-76. PubMed ID: 24221641
    [Abstract] [Full Text] [Related]

  • 12. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group.
    Lancet Neurol; 2011 Jun 14; 10(6):520-9. PubMed ID: 21571593
    [Abstract] [Full Text] [Related]

  • 13. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
    Montalban X, Comi G, O'Connor P, Gold S, de Vera A, Eckert B, Kappos L.
    Mult Scler; 2011 Nov 14; 17(11):1341-50. PubMed ID: 21727148
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
    Agashivala N, Kim E.
    Clin Ther; 2012 Jul 14; 34(7):1583-90. PubMed ID: 22749258
    [Abstract] [Full Text] [Related]

  • 15. Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.
    Al-Hashel J, Ahmed SF, Behbehani R, Alroughani R.
    CNS Drugs; 2014 Sep 14; 28(9):817-24. PubMed ID: 25011422
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of reduced fingolimod dosage treatment.
    Yamout BI, Zeineddine MM, Sawaya RA, Khoury SJ.
    J Neuroimmunol; 2015 Aug 15; 285():13-5. PubMed ID: 26198913
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.
    Chinea Martinez AR, Correale J, Coyle PK, Meng X, Tenenbaum N.
    Adv Ther; 2014 Oct 15; 31(10):1072-81. PubMed ID: 25245812
    [Abstract] [Full Text] [Related]

  • 18. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A, Castilló J, Montalban X.
    Expert Opin Pharmacother; 2010 May 15; 11(7):1183-96. PubMed ID: 20367536
    [Abstract] [Full Text] [Related]

  • 19. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
    Cohen JA, Barkhof F, Comi G, Izquierdo G, Khatri B, Montalban X, Pelletier J, Eckert B, Häring DA, Francis G.
    J Neurol; 2013 Aug 15; 260(8):2023-32. PubMed ID: 23632946
    [Abstract] [Full Text] [Related]

  • 20. Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
    Voon V, Saiva L, O'Kelly S, Keane D.
    Eur J Clin Pharmacol; 2014 Mar 15; 70(3):373-5. PubMed ID: 24309839
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.